Literature DB >> 1530947

Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin.

E A Wayner1, N L Kovach.   

Abstract

It has been shown that the alpha 4 beta 1 integrin is the lymphocyte receptor for the carboxy terminal cell-binding domain of fibronectin which comprises adhesion sites in Hep 2 and a high affinity site, CS-1, in the type III connecting segment or V (for variable) region. In the present studies, using a series of peptides derived from CS-1, we identify the tripeptide leu-asp-val (LDV), as the minimal peptide capable of supporting stable lymphocyte or melanoma cell adhesion. However, only cells which expressed an active form of the alpha 4 beta 1 complex were capable of attaching to and spreading on LDV peptide. On a molar basis, LDV minimal peptides were either not active or 10-20 times less active than intact CS-1 in promoting the adhesion of lymphocytes expressing the resting form of the receptor. In cells which express the high avidity form of the receptor, LDV and CS-1 were equally effective in promoting cell adhesion and spreading. The avidity of the alpha 4 beta 1 complex could be altered with mAbs to beta 1 which specifically activate beta 1 dependent function. The high avidity form of the alpha 4 beta 1 complex could be induced on U937 cells, T, and B lymphoblastoid cell lines, or PHA-stimulated T cell blasts. Resting PBL could not be induced to bind LDV peptide conjugates by activating antibodies to beta 1 implying that two signals are required for LDV recognition by T cells. In conclusion, these data show clearly that the minimal peptide for the alpha 4 beta 1 complex in CS-1 is the LDV sequence. Although numerous cell populations can interact with intact CS-1 only cells which express an active alpha 4 beta 1 complex can bind the LDV sequence. This implies that cell interaction with the carboxy terminal cell-binding domain of fibronectin can be regulated at several levels: (a) alpha 4 beta 1 expression; (b) activation of the alpha 4 beta 1 complex; and (c) alternate splicing of CS-1 into V+ isoforms of fibronectin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530947      PMCID: PMC2289302          DOI: 10.1083/jcb.116.2.489

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  26 in total

1.  Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor.

Authors:  R Pytela; M D Pierschbacher; E Ruoslahti
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

2.  Cell-type-specific fibronectin subunits generated by alternative splicing.

Authors:  J I Paul; J E Schwarzbauer; J W Tamkun; R O Hynes
Journal:  J Biol Chem       Date:  1986-09-15       Impact factor: 5.157

3.  Identification of two distinct regions of the type III connecting segment of human plasma fibronectin that promote cell type-specific adhesion.

Authors:  M J Humphries; A Komoriya; S K Akiyama; K Olden; K M Yamada
Journal:  J Biol Chem       Date:  1987-05-15       Impact factor: 5.157

4.  Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1.

Authors:  A P Mould; L A Wheldon; A Komoriya; E A Wayner; K M Yamada; M J Humphries
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

5.  Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1.

Authors:  J L Guan; R O Hynes
Journal:  Cell       Date:  1990-01-12       Impact factor: 41.582

6.  The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine.

Authors:  A Komoriya; L J Green; M Mervic; S S Yamada; K M Yamada; M J Humphries
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

7.  Adhesion of lymphoid cell lines to fibronectin-coated substratum: biochemical and physiological characterization and the identification of a 140-kDa fibronectin receptor.

Authors:  N S Liao; J St John; Z J Du; H T Cheung
Journal:  Exp Cell Res       Date:  1987-08       Impact factor: 3.905

8.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.

Authors:  A R Kornblihtt; K Umezawa; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

9.  The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa.

Authors:  E A Wayner; W G Carter; R S Piotrowicz; T J Kunicki
Journal:  J Cell Biol       Date:  1988-11       Impact factor: 10.539

10.  Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.

Authors:  E A Wayner; A Garcia-Pardo; M J Humphries; J A McDonald; W G Carter
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

View more
  31 in total

1.  Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins.

Authors:  T W Kuijpers; R A Van Lier; D Hamann; M de Boer; L Y Thung; R S Weening; A J Verhoeven; D Roos
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  The integrin VLA-2 binds echovirus 1 and extracellular matrix ligands by different mechanisms.

Authors:  J M Bergelson; B M Chan; R W Finberg; M E Hemler
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

3.  Rac regulates integrin-mediated spreading and increased adhesion of T lymphocytes.

Authors:  C D'Souza-Schorey; B Boettner; L Van Aelst
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

4.  A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Cidonia L Vituri; Mercedes Hernández del Cerro; María José Terol; Juan P Albar; Germán Rivas; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

Review 5.  Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.

Authors:  T W Kuijpers
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

7.  Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin.

Authors:  P T Shih; M J Elices; Z T Fang; T P Ugarova; D Strahl; M C Territo; J S Frank; N L Kovach; C Cabanas; J A Berliner; D K Vora
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

8.  NG2, a novel proapoptotic receptor, opposes integrin alpha4 to mediate anoikis through PKCalpha-dependent suppression of FAK phosphorylation.

Authors:  N E Joo; T Watanabe; C Chen; M Chekenya; W B Stallcup; Y L Kapila
Journal:  Cell Death Differ       Date:  2008-02-22       Impact factor: 15.828

9.  Adhesion to fibronectin primes eosinophils via alpha 4 beta 1 (VLA-4).

Authors:  A R Anwar; G M Walsh; O Cromwell; A B Kay; A J Wardlaw
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

10.  Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature.

Authors:  M J Elices; V Tsai; D Strahl; A S Goel; V Tollefson; T Arrhenius; E A Wayner; F C Gaeta; J D Fikes; G S Firestein
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.